The safety and efficacy of foseamet for prevention of cytomegalovirus (CMV) infection was evaluated in 19 CMV-seropositive bone marrow transplant (BMT) recipients. All patients reeeh'ed intermittent intra\'enous (iv) foscamet: 40 mg/kg every 8 h from 7 days before to day 30 after BMT, then 60 mg/kg once a day until day 75. The main toxicity was transient renal dysfunction, with a >50 pmol/L increase in serum creatinine above baseline in 5 of the 7 autograft recipients and in 6 of the 12 allograft recipients. Only4 allograft recipients developed CMV infection during foscarnet prophylaxis, and no patient s!\()wed evidence ofCMV disease. Because 3 allograft recipients receiving concomitant ivamphotericin B showed rapid impairment of renal function, foscarnet prophylaxis should not be given to allograft recipients requiring amphotericin B; otherwise, foscarnet prophylaxis at this dose appears safe after BMT.
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Infection due to cytomegalovirus (CMV) causes significant morbidity and mortality among bone marrow transplant (BMT) recipients [I] . In two published series, thc probability ofCMV infection within the first 100 days after BMT among patients who were CMV-seropositive before transplant was up to 80% and 60% for allograft and autograft recipients. respectively [2. 3] . Mortality was primarily related to CMV pneumonia. which developed in 37% of allograft and in 22% of autogmft recipients who had cvidcncc of activc CMV infcction [2. 3] . Thus. thc prevcntion of CMV infcction and disease after DMT is of foremost importance.
Antiviral chemotherapy aimed at preventing reactivation oflatent virus may be the most promising approach to CMV prophylaxis both among CMV-seropositivc autograft and allograft recipients and among seronegative allograft recipients who have a seropositive marrow donor. CMV drug prophylaxis should covcr thc carly pcriod aftcr BMT in which a deficiency in CMV-specific immunity can contribute to the risk of severe CMV disease [4] .
Thc antiviral agent acyclovir given intmvenously at high doses was shown to be partially effective in preventing CMV infection and disease among seropositive BMT recipients [5] .
Ganciclovir. which is more active than acyclovir against CMV [6] . was cvaluated in two recent prospective randomizcd controlled trials among BMT rccipients [7. 8] . In these two studies of early treatment with 'ganciclovir in patients who had engrafted (increased neutrophil count after BMT) and who devcloped CMV e;x;cretion, the incidence ofsubsequent CMV discase was significantly reduced. but sevcre neutropenia occurred in 30%-=35% of treated patients [7. 8] .
The antiviral drug foscarnet (trisodium phosphonoformate) inhibits herpesvirus DNA polymerasc activity [9. 10] and was shown to suppress replication of both laboratory strains and clinical isolates ofCMV in vitro [11] [12] [13] . Clinical studies among transplant recipients and patients with AIDS who received foscarnet treatment for scvere CMV diseasc have shown therapeutic effects and indicate that rerial dysfunction is the main adverse experience associated with foscarnet. whereas neutrophil counts do not appear to be substantially affected [14] . Foscarnet could prove as efficient as ganciclovir in preventing CMV disease in BMT recipients but could be Icss toxic to thc bone marrow and could thercfore be used as CMV prophyla;x;is starting before BMT. In view ofcmerging resistance ofCMV to ganciclovir [15] [16] [17] [18] . foscamet also could be used as an alternative prophylactic regimen if resistance to ganciclovir is documcntcd.
We report a prospective phase I-II trial of intermittent intravcnous foscamet for thc prcvention of CMV infection and disease among CMV~seropositivc autologous and allogeneic DMT recipients. Except for one pilot trial in which 10 CMV-scropositivc marrow recipients werc givcn continuous intravenous administration offoscarnct for prophylaxis [19] , no data on prophylactic regimens using foscarnet among BMT recipients havc yct becn published. 
Patients and Methods

474
Scattle were selected for study if they underwent autologous or allogeneic BMT for hematologic malignancy and if they were CMV-seropositive before transplant. Exclusion criteria were age <12 years. a known allergy to foscarnet. ongoing treatment with acyclovir or ganciclovir. grafl-versus-host disease (GVHD) prophylactic regimen other than cyclosporine plus methotrexate among allografl recipients [20] . proven CMV disease before transplant. or renal insufficiency (serum creatinine> 1331lmol/ L) at the time ofinitiation offoscarnet prophylaxis. Patients who underwent a second marrow transplant or who received a T cell-depleted marrow grafl were also excluded.
The methods of pretransplant conditioning and posttransplant care have been described [21. 22] . Allogeneic transplant. recipients were given cyclosporine plus a short course of me thotrexate as GVIID prophylaxis [20] . No patient received intravenous immune globulins for prevention of infections or GVHD. Since every patient was CMV-seropositive. blood products transfused during the study period were not screened for CMV.
Protocol design. Because the main adverse effect offoscarnet is renal dysfunction [14] . foscarnet was first evaluated in autograft recipients ...Au tografl recipients do not receive cyclosporinc. which has known nephrotoxic potential [23] . Once foscarnet proved safe in autografl recipients. the drug was administered to allogeneic marrow recipients.
Foscarnet sodium solution (Astra Clinical Associates. Hopkinton. MA) was supplicd in 500-mL glass bottles at 24 mg/mL in an isotonic solution with HCI to adjust pH to 7.4. Each dose was administered through a central venous line by using an infusion pump. Two regimens offoscarnet were evaluated. The inpatient regimen was a I-h infusion of foscarnet at 40 mglkg every 8 h beginning 7 days before BMT and continuing to day 30 after DMT or until discharge from hospital if earlier. The calculated total daily dose of 120 mglkg corresponds to twothirds of the dosage (180 mg/kglday) used as induction treatment for CMV retinitis in patients with AIDS [24. 25] . The outpatient regimen was a I-h intravenous infusion of foscarnet daily at a dose of 60 mg/kg given until day 75 after BMT.
Because foscarnet is eliminated by renal excretion [14] . the dosage was adjusted when the calculated creatinine clearance was < 1.4 mL/min/kg. Continuous adjustments were made until clearance dropped to <0.4 mL/min/kg. at which time treatment was stopped. Patients who developed CMV disease were eligible for available therapy protocols. and participation in the foscarnet trial was·terminated. If treatment of herpes simplex virus or varicella-zoster virus infection required acyclovir therapy. foscarnet treatment was interrupted and resumed on discontinuation of acyclovir therapy.
Phase I-safety.
To assess potential drug toxicity. the follow-. ing data were recorded daily for inpatients and at least three times a week for outpatients: white blood cell (WBC) counts with differential counts. hemoglobfn level. platelet counts, and serum creatinine level. Serum calcium, magnesium. and phosphorus concentrations were obtained and liver function tests were done three times a week. Any clinical symptoms or signs possibly related to foscarnet treatment \vere recorded daily. The rapidity of engraflment during foscarnet treatment was evaluated by determining the number of days required for patients to reach WOC counts of 1.0 X I09/L. absolute neutrophil counts of Phase Il-ej] icacy. Viral cultures were prepared from throat. urine. and blood specimens from each patient before treatment and weekly during and after treatment for a minimum of 100 days aner transplant. Viral cultures from other sites or from tissue specimens were prepared when clinically indicated. The clinical specimens were inoculated onto monolaycrs ofhuman foreskin fibroblasts and observed for up to 5 weeks. Positive cultures were identified by the appearance of typical cytopathic effects, and, in the case of equivocal results, further identification was done by indirect immunonuorescence with murine monoclonal antibodies (Syva. Palo Alto. CA). Serum samples obtained weekly were tested for' IgG antibody to CMV by ELISA (CMV Stat: Whittaker M.A. Bioproducts. Walkersville. MD).
CMV infection was defined as excretion of the virus or presence of CMV in tissue specimens but without clinical symptoms. CMV discase was defined as presence of CMV in tissue specimens or in bronchoalveolar lavage (BAL) nuid with associated clinical symptoms and signs, Pharmacokinetics of foscamet. Blood specimens were obtained from each patient for pharmacokinetic studies at steady slate afler I week offoscarnet treatment and at weekly intervals thereafler. Blood (2 mL) was drawn immediately before and at the end of a given foscarnet infusion and again before the next consecutive infusion of the drug. Foscarnet plasma levels were determined by high-performance liquid chromatography with electrochemical detection as described (26] . The lowest concentration offoscarnet detcctable by this assay is 33Ilmol/L. Calculation of plasma half-lives (tl/2) of foscarnet was done as described (27] .
Rcsults
The clinical characteristics of the 19 patients enrolled in the study are summarized in table I. Duration of foscarnet prophylaxis. median daily dose. and reasons for premature discontinuation. are in table 2.
Safety of Foscarnet
Rel/alful/ctiol/.
The main toxicity associated with foscarnet prophylaxis was impaired renal function (table 3) . Of the 7 autograft recipients, 6 (86%) developed renal toxicity. with an increase in serum creatinine above baseline of>50 Ilmol/ L in 5 patients (71%). In 2 of these 5 patients. impairment was severe enough to require termination offoscarnet (aller 18 and 8 days of foscarnet treatment) and hemodialysis.
Of the 2 requiring hemodialysis, I patient had acute toxicity consisting of diffuse skin rash, hypotension. and renal failure (peak serum creatinine. 733 Ilmol/L). This patient had been receiving concomitant treatment with granulocytemacrophage colony-stimulating factor and intravenous amphotericin B, which could have contributed to toxicity. Both foscarnet and amphotericin D were discontinued (on day 10 Table 3 . Toxicity during foscarnet treatment in marrow transplant recipients for prevention of cytomegalovirus infection. Table 2 . Duration and dosage of foscarnet treatment in marrow transplant recipients for prevention of cytomegalovirus infection.
NOTE. Cy. c)'clophosphamide;FfBi. frnctionatedtotal body irrndia· tion; Bu.busulfan;VPI6. etoposide;BCNU.C:lrmustine .
• Includes J patientwho also rcceivedbusulfanforconditioning.
• 2 related to renal toxicity; I died of idiopathic intcrs.titial pneumonia after32 daysoftrcatmcnt: I diedofcardiactoxicityrelatedto chemothcrapy aller 26 daysoftreatment; I had leukemicrebpse after44 daysoftreatmen!. , 3 relatedto renal toxicity;3 requiredintravenousamphotericinB therapy; 1 requircdacyclovirforornl hcrpessimplexvirusinfection. after BMT). and renal function was eventually restored. The second patient showed an immediate reaction on the day of the marrow infusion that was attributed to dimethyl sulfoxide used for cryopreservation of bone marrow. Although serum creatinine was 71 /-lmol/L when foscarnet was stopped (on the day of BMT). creatinine levels rose to a peak of 804 /-lmol/L in this patient. with recovery to 141 /-lmol/L by day 37 after BMT. Whether renal failure in this patient was related to foscarnet treatment could not be determined. /-lmol/L in 6 (50%). Three allograft recipients showed rapid impairment of renal function requiring premature discontinuation of foscarnet after 16, 17, and 19 days of treatment. Two of the 3 required hemodialysis. One of the dialysed patients did not improve and died on day 40 after BMT (32 days after foscarnet was stopped) from gram-negative sepsis, GVHD, and multiorgan failure. Renal function in the other 2 patients normalized within 10 and 14 days after discontinuation of foscarnet. These 2 patients had received intravenous amphotericin B during the 3 days before foscarnet treatment was stopped. An additional allograft recipient who was given foscarnet and concqmitant amphotericin B developed a rapid increase in serum creatinine (peak. 283 /-lmol/L). which did not necessitate premature withdrawal from the study but \vhich required temporary discontinuation of foscarnet for 8 days. On the basis of the experience in these 3 patients, concomitant use of foscarnet and intravenous amphotericin B in allograft recipients also receiving cyclosporine was subsequently precluded .
Electrolytes.
Hypocalcemia and hypophosphatemia were frequent after initiation offoscarnet treatment ( Supplied by The Bfitish Library -"The world's knowledge" evidence of CMV infection while on foscarnet prophylaxis. One autograll recipient had a BAL for pulmonary infiltrates aller 16 days of foscarnet treatment that was negative for CMV. Two (29%) of the 7 autograll recipients had CMV recovered from urine specimens 31 and 67 days after foscarnet was stopped. No other viruses were isolated in autologous BMT recipients.
CMV infection occurred in 4 (33%) of the 12 allograft recipients during foscarnet treatment. Two were receiving the inpatient regimen and 2 the outpatient regimen. In 4 additional patients (33%). CMV infection developed a median of36 days (range, 24-52) aller the drug was discontinued.-cMV disease did not develop in any allograft recipient during'foscarnet prophylaxis. However. 2 allograft recipients (17%) developed BAL-proven CMV pneumonia 37 and 42 days after foscarnet was stopped. and both died.
Herpes simplex virus infec.tion was documented in 4 allograft recipients (33%) during foscarnet treatment and in 2 (17%) aller the end of treatment. One allograll recipient (8%) had adenovirus recovered from the throat and from urine 48 days after discontinuation of foscarnet.
r Table 5 . Virologic results during and aller foscamettn:atment in marrow transplant n:cipients for prevention of cytomegalovirus (CMV) infection.
NOTE. Rile. red blood cells: WBC. white blood cells. Data are median (range).
, Patients who died before reaching specific cell count while on foscarnet treatment were exeluded.
t Counts maintained on at least 2 consecutive days without platelet transfusion support.
During foscarnet treatment
AOer foscarnet treatment changes in serum calcium, magnesium. or phosphorus levels. but all were supplemented by intravenous infusions when serum levels were low.
LiI'er flll/ctiol/.
Seven patients had liver failure. defined as total serum bilirubin >85 ILmol/L, aspartate aminotransferase >200 units/L. or both (table 3). All cases appeared to be unrelated to foscarnet use. The decision to terminate foscarnet during the study was never based on liver toxicity.
Hematologic effects. The results of hematologic monitoring before and during foscarnet treatment are shown in table 4. Hemoglobin levels dropped during treatment for all autograft recipients and for 10 (83%) of 12 allograft recipients, reaching a minimum at a median of 13 and 15 days. respectively, after initiation of foscarnet, which corresponded to the end of the first week after BMT. The median number of red blood cell transfusions per patient was similar when the 7 patients who completed a full course of foscarnet prophylaxis were compared with the entire study population (16 vs. 14 units). No patient had foscarnet discontinued because of hematologic toxicity .. 'Two patients with CMV viremia during foscarnet treatment began to excrete CMV from throat and urine aOer completion offoscarnet prophylaxis.
JID 1992:166 (Seplember) Foscarnel to Prevenl CMV Infeclion 477 Table 6 . Peak and trough foscamet plasma levels at steady state during intermittent intravenous (iv) lreatment in marrow transplant recipients for prevention of cytomegalovirus infection. Pharmacokinetics of Foscarnct Table 6 shows the steady-state peak and trough plasma levels of foscarnel during the inpatient and outpatient regimens at full doses and at reduced doses when the creatinine clearance was 0.4-1.3 mLfminfkg. Complete data were available for calculations of plasma tl/2 offoscarnet in 3 autograft and 9 allograft recipients. During the inpatient regimen, median plasma tiP of foscarnet was 2.9 h (range, 2.1-8.4) among autograft recipients and 6.2 h (range, 1.6-15.9) among allograft recipients. Because most trough plasma levels were below the limit of detectability during the outpatient foscarnet regimen (table 6) . plasma tl/2 could be determined in only I allograft recipient and was 6 h. There was no correlation between the magnitude of plasma tiP offoscamet and the occurrence ofCMV infeclion.
AUlograft recipients Allograft recipients
Discussion
The most serious toxicity associated with foscamet pro-' phylaxis in our patients was impaired renal function. An increase in serum creatinine of >50 JlmolfL above baseline levels was observed in II (58%) of the 19 patients during foscarnet treatment. Renal insufficiency led to premature withdrawal froin the study of 5 patients (26%). The relationship of renal insufficiency to foscarnet use was considered possible in 4 of these 5 patients and was judged unevaluatable in the other. The frequency and severity of renal toxicity in our study was in the range of that in other studies ofallogeneic BMT recipients and AIDS patients [24, 25. 28-32] .
Among our allograft recipients. who all r~ceived cyclosporine. it rapidly became clear that foscarnet and amphotericin B could not be used simultaneously with!>ut development of renal insufficiency. Subsequently, foscarnet was discontinued whenever intravenous amphotericin B was needed in a patient receiving cyclosporine. However. foscarnet could be used safely with amphotericin B among autograft recipients who do not receive cyclosporine.
A recent study suggests that renal toxicity associated with the use offoscarnet can be prevented by hydration with intravenous isotonic saline given daily during treatment [32] . In that study. only I (4%) of27 patients with AIDS and CMV retinitis who received foscarnet with hydration developed acute renal failure. Peak serum creatinine levels in this group of patients were significantly lower than in a historical control group that had received the same foscarnet regimen without hydration [32] . Reduction of renal toxicity would allow a larger proportion ofBMT recipients to receive a full course of foscarnet prophylaxis. which may reduce the incidence ofCMV infection after transplant.
Abnormalities of serum electrolytes were common but not associated with clinical symptoms or signs. suggesting they were minor adverse effects of foscamet prophylaxis. Clinical manifestations may have been prevented by intravenous replacement of these compounds when required. In a study of 10 AIDS patients. abnormalities of serum calcium and phosphorus levels were observed in 9 cases but were not accompanied by symptoms and normalized after foscarnet induction treatment was completed [24] . After BMT, the causes ofhypocalcemia. hypophosphatemia. or hypomagnesemia are probably multifactorial. Thus. the contribution offoscamet to these conditions in our study remains unclear.
A decrease in hemoglobin levels was frequently observed in this study and was most common early after BMT. However, the requirements of red blood cell transfusions among patients whO'received a full course offoscarnet prophylaxis did not exceed those reported in earlier studies from our transplant center among both allograft and autograft recipients who did not receive foscarnet [33. 34] . The rapidity of engraftment after BMT was also similar to that among autologous and allogeneic BMT recipients who were not treated with foscarnet (3. 35] . Premature discontinuation of foscarnet prophylaxis was not based on hematologic toxicity in any Reusser et CMV infection was prevented in all of our autograft recipients but occurred in 33% of allograft recipients during treatment. No patient in this study showed evidence of CMV disease while receiving foscarnet prophylaxis. These results compare favorably with those from an earlier pilot study in which 50% of CMV-seropositive allogeneic 8MT recipients receiving continuous infusions of prophylactic foscarnet developed CMV infection [19] . Peak plasma levels obtained with intermittent infusion of the drug in our study were more than double the levels measured with continuous infusion of foscarnet in that previous trial. which may explain the improved efficacy.
With one exception [17] , earlier studies of foscarnet among BMT recipients used continuous intravenous infusions to administer the drug [13. 19, 28, 29. 36-38] . In one of these studies that reported data on pharmacokinetics [29] , the steady-state serum levels of foscarnet in 13 allogeneic BMT recipients who received a daily dose of foscarnet similar to the dose in our inpatient regimen were 273 ±43 pmol! L (mean ± SE). In our study. the median peak plasma concentrations of foscarnet obtained during the inpatient and outpatient regimens among autograft and allograft recipients ranged from 256 to 387 pmol/L. The trough plasma levels of foscarnet. however, were usually <33 pmol/L, the detection limit of the assay (26] . Most clinical isolates of CMV are inhibited at concentrations of foscarnet of200-400 pmol!L in in vitro cell cultures [14, 18] . Our results indicate that continuously elevated plasma concentrations offoscarnet do not appear to be necessary to prevent CMV infection in 8MT recipients.
Prevention of CMV infection and disease appeared effective only while patients were actively taking the drug. After discontinuation of foscarnet, CMV infection occurred in ,2 autograft (29%) and 4 allograft recipients (33%), and CMV pneumonia developed in 2 allogeneic 8MT recipients (17%). However, except for I allograft recipient who had CMV excretion in the throat and urine after a full course offoscarnet prophylaxis. all of these patients were prematurely withdrawn from the study and did not receive alternative antiviral prophylaxis (data not shown). It remains conjectural whether a full course of foscarnet treatment or the replacement offoscarnet by drugs such as acyclovir [5] or gancicIovir [7, 8] might have altered the course.
Our data suggest that intermittent intravenous foscarnet prophylaxis is effective in preventing CMV disease among patients who tolerate the full course of treatment. However, foscarnel should not be given to allogeneic 8MT recipients receiving cyclosporine who require intravenous amphotericin B. With that exception, prophylaxis at the doses used appears to be safe after both autologous and allogeneic 8MT.
